Name | (2R)-3-{(2R,6S)-2,6-Bis[2-(4-methoxyphenyl)ethyl]-1-piperidinyl}-1,2-propanediol hydrochloride (1:1) |
---|---|
Synonyms |
(2R)-3-{(2R,6S)-2,6-Bis[2-(4-methoxyphenyl)ethyl]-1-piperidinyl}-1,2-propanediol hydrochloride (1:1)
1,2-Propanediol, 3-[(2R,6S)-2,6-bis[2-(4-methoxyphenyl)ethyl]-1-piperidinyl]-, (2R)-, hydrochloride (1:1) |
Description | GZ-793A is an orally active and selective vesicular monoamine transporter-2 (VMAT2) inhibitor, with an Ki of 0.029 µM. GZ-793A inhibits the neurochemical effects of methamphetamine (METH)-induced dopamine release. GZ-793A can be used for research of METH addiction[1][2][3]. |
---|---|
Related Catalog | |
Target |
Ki: 0.029 µM (VMAT2)[1]. |
In Vivo | GZ-793A (30, 60, 120 or 240 mg/kg; p.o.; once) decreases the number of METH infusions self-administered across each time interval evaluats in a dose-dependent manner[1]. GZ-793A (1-100 µM; 90 min) inhibits METH (5 µM)-evoked fractional dopamine releases[2]. Animal Model: Adult male Sprague-Dawley rats[1]. Dosage: 30, 60, 120 or 240 mg/kg Administration: Oral administration; once. Result: Decreased the number of METH infusions self-administered in a dose-dependent manner, and with an ~85% reduction at the highest dose (240 mg/kg). Decreased the METH self-administration produced by lasted at least 180 min. Animal Model: Male Sprague-Dawley rats (250–275 g; 9-week-old; 0.5 mm thick rats coronal striatal slices are used)[2]. Dosage: 1-100 µM Administration: 90 min Result: Inhibited methamphetamine-evoked dopamine released in a concentration-dependent manner. |
References |
Molecular Formula | C26H38ClNO4 |
---|---|
Molecular Weight | 464.037 |
Exact Mass | 463.248932 |